242 results
8-K
EX-99.1
JAZZ
Jazz Pharmaceuticals plc
1 May 24
Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results
4:06pm
and development
% of total revenues
Acquired in-process research and development
Income tax expense (benefit)1
Effective tax rate 1
1.The GAAP income tax … percentages)
Non-GAAP adjusted:
Cost of product sales
Gross margin
Selling, general and administrative
% of total revenues
Research and development
8-K
EX-99.1
JAZZ
Jazz Pharmaceuticals plc
28 Feb 24
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results
4:06pm
)
GAAP:
Cost of product sales
Gross margin
Selling, general and administrative
% of total revenues
Research and development
% of total revenues
Acquired … in-process research and development
Intangible asset impairment charge
Income tax benefit
Effective tax rate 1
1.The GAAP effective tax rate decreased
8-K
EX-10.1
9cp2t0cfexk rlhzi0
25 Jan 24
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-99.1
6ed 7muamg9w
8 Jan 24
Results of Operations and Financial Condition
7:45am
8-K
EX-99.1
isphflpevmov3s
8 Nov 23
Jazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial Guidance
4:07pm
8-K
EX-99.1
tc14xd4dxr
9 Aug 23
Jazz Pharmaceuticals Announces Second Quarter 2023 Financial Results and Raises 2023 Full Year Financial Guidance
4:07pm
8-K
8w5ci98gfdee3s7odk3
22 Jun 23
Regulation FD Disclosure
4:05pm
8-K
EX-99.1
bodnt
10 May 23
Jazz Pharmaceuticals Announces First Quarter 2023 Financial Results and Affirms 2023 Financial Guidance
4:08pm
8-K
EX-99.1
zlhftb0u3sfim2 p889u
21 Dec 22
Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab
7:40am
8-K
EX-2.1
ourpd19658dn0
5 Dec 22
Completion of Acquisition or Disposition of Assets
4:16pm